Q32 Bio Inc. (QTTB)
(Real Time Quote from BATS)
$43.74 USD
+0.26 (0.60%)
Updated Sep 3, 2024 10:14 AM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Q32 Bio Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 83 | 175 | 156 | 217 | 262 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 6 | 36 | 2 | 4 |
Total Current Assets | 84 | 181 | 192 | 220 | 267 |
Net Property & Equipment | 0 | 1 | 2 | 37 | 43 |
Investments & Advances | 0 | 26 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 2 | 1 | 1 |
Total Assets | 85 | 228 | 212 | 264 | 311 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 1 | 2 | 5 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 19 | 11 | 10 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 3 | 6 | 2 |
Total Current Liabilities | 12 | 23 | 17 | 23 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 1 | 32 | 30 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 10 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 12 | 50 | 42 | 68 | 52 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 615 | 608 | 594 | 524 | 458 |
Retained Earnings | -542 | -429 | -424 | -328 | -200 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 73 | 178 | 170 | 196 | 259 |
Total Liabilities & Shareholder's Equity | 85 | 228 | 212 | 264 | 311 |
Total Common Equity | 73 | 178 | 170 | 196 | 259 |
Shares Outstanding | 3.20 | 3.20 | 3.10 | 2.50 | 2.50 |
Book Value Per Share | 22.81 | 55.62 | 54.73 | 78.40 | 103.40 |
Fiscal Year End for Q32 Bio Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 108 | 135 | 83 | 103 | 127 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 3 | 1 | 3 | 4 |
Total Current Assets | 112 | 138 | 84 | 107 | 131 |
Net Property & Equipment | 2 | 2 | 0 | 0 | 1 |
Investments & Advances | 3 | 5 | 0 | 14 | 17 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 0 | 0 | 0 |
Total Assets | 124 | 152 | 85 | 140 | 169 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 5 | 3 | 8 | 3 |
Current Portion Long-Term Debt | 0 | 3 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 20 | 7 | 16 | 18 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 5 | 0 | 0 | 0 |
Total Current Liabilities | 17 | 33 | 12 | 25 | 23 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 13 | 9 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 55 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 91 | 104 | 12 | 52 | 50 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 237 | 235 | 615 | 614 | 612 |
Retained Earnings | -203 | -186 | -542 | -526 | -493 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 34 | 49 | 73 | 88 | 119 |
Total Liabilities & Shareholder's Equity | 124 | 152 | 85 | 140 | 169 |
Total Common Equity | 34 | 49 | 73 | 88 | 119 |
Shares Outstanding | 11.90 | 11.90 | 3.20 | 3.20 | 3.20 |
Book Value Per Share | 2.82 | 4.10 | 22.81 | 27.57 | 37.31 |